These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

447 related articles for article (PubMed ID: 16631458)

  • 1. Mechanisms leading to the development of hormone-resistant prostate cancer.
    Kasper S; Cookson MS
    Urol Clin North Am; 2006 May; 33(2):201-10, vii. PubMed ID: 16631458
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mechanisms of prostate cancer progression to androgen independence.
    McPhaul MJ
    Best Pract Res Clin Endocrinol Metab; 2008 Apr; 22(2):373-88. PubMed ID: 18471793
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drug insight: role of the androgen receptor in the development and progression of prostate cancer.
    Taplin ME
    Nat Clin Pract Oncol; 2007 Apr; 4(4):236-44. PubMed ID: 17392714
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Hormone-resistant epithelial cancer of the prostate].
    Medvedev VL
    Urologiia; 2001; (4):29-33. PubMed ID: 11569231
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular determinants of resistance to antiandrogen therapy.
    Chen CD; Welsbie DS; Tran C; Baek SH; Chen R; Vessella R; Rosenfeld MG; Sawyers CL
    Nat Med; 2004 Jan; 10(1):33-9. PubMed ID: 14702632
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel secondary hormonal therapy in advanced prostate cancer: an update.
    Van Allen EM; Ryan CJ
    Curr Opin Urol; 2009 May; 19(3):315-21. PubMed ID: 19342958
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Finnish multicenter study comparing intermittent to continuous androgen deprivation for advanced prostate cancer: interim analysis of prognostic markers affecting initial response to androgen deprivation.
    Salonen AJ; Viitanen J; Lundstedt S; Ala-Opas M; Taari K; Tammela TL;
    J Urol; 2008 Sep; 180(3):915-9; discussion 919-20. PubMed ID: 18635219
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Secondary hormonal therapy for advanced prostate cancer.
    Lam JS; Leppert JT; Vemulapalli SN; Shvarts O; Belldegrun AS
    J Urol; 2006 Jan; 175(1):27-34. PubMed ID: 16406864
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunomagnetic quantification of circulating tumor cells as a prognostic factor of androgen deprivation responsiveness in patients with hormone naive metastatic prostate cancer.
    Okegawa T; Nutahara K; Higashihara E
    J Urol; 2008 Oct; 180(4):1342-7. PubMed ID: 18707699
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Key targets of hormonal treatment of prostate cancer. Part 1: the androgen receptor and steroidogenic pathways.
    Vis AN; Schröder FH
    BJU Int; 2009 Aug; 104(4):438-48. PubMed ID: 19558559
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prostate cancer cells increase androgen sensitivity by increase in nuclear androgen receptor and androgen receptor coactivators; a possible mechanism of hormone-resistance of prostate cancer cells.
    Fujimoto N; Miyamoto H; Mizokami A; Harada S; Nomura M; Ueta Y; Sasaguri T; Matsumoto T
    Cancer Invest; 2007 Feb; 25(1):32-7. PubMed ID: 17364555
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Secondary hormonal therapy.
    Smith DC
    Semin Urol Oncol; 1997 Feb; 15(1):3-12. PubMed ID: 9050134
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Managing prostate cancer: the role of hormone therapy.
    Ramirez ML; Keane TE; Evans CP
    Can J Urol; 2007 Dec; 14 Suppl 1():10-8. PubMed ID: 18163939
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regulation of androgen receptor signaling in prostate cancer.
    Dehm SM; Tindall DJ
    Expert Rev Anticancer Ther; 2005 Feb; 5(1):63-74. PubMed ID: 15757439
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Overcoming castration resistance in prostate cancer.
    Tsao CK; Small AC; Galsky MD; Oh WK
    Curr Opin Urol; 2012 May; 22(3):167-74. PubMed ID: 22472508
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase II study of tamoxifen in hormone-resistant metastatic prostate cancer: possible relation with prolactin secretion.
    Lissoni P; Vigano P; Vaghi M; Frontini L; Giuberti C; Manganini V; Casu M; Brivio F; Niespolo R; Strada G
    Anticancer Res; 2005; 25(5):3597-9. PubMed ID: 16101186
    [TBL] [Abstract][Full Text] [Related]  

  • 17. What is the role of androgen deprivation therapy in the treatment of locally advanced prostate cancer?
    Kollmeier MA; Zelefsky MJ
    Nat Clin Pract Urol; 2008 Nov; 5(11):584-5. PubMed ID: 18813218
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Longitudinal analysis of androgen deprivation of prostate cancer cells identifies pathways to androgen independence.
    D'Antonio JM; Ma C; Monzon FA; Pflug BR
    Prostate; 2008 May; 68(7):698-714. PubMed ID: 18302219
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetic polymorphism in EGF is associated with prostate cancer aggressiveness and progression-free interval in androgen blockade-treated patients.
    Teixeira AL; Ribeiro R; Cardoso D; Pinto D; Lobo F; Fraga A; Pina F; Calais-da-Silva F; Medeiros R
    Clin Cancer Res; 2008 Jun; 14(11):3367-71. PubMed ID: 18519765
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The mutated androgen receptor and its implications for the treatment of metastatic carcinoma of the prostate.
    Middleman MN; Lush RM; Figg WD
    Pharmacotherapy; 1996; 16(3):376-81. PubMed ID: 8726595
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.